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T

he Spring 2018 edition of Neurotransmitter demonstrates that the rigorous fields of
the basic and clinical neurosciences have spiritual and artful sides.
Since its inception, Neurotransmitter has been decorated with art that plays off
the subjects of its articles. This edition produces its own art. Within these pages, you
can see a beautiful microscopic image of nerve bodies and their supporting cells
taken by first-year MD student Aslam Akhtar, PhD, as part of his research studies of
the olfactory bulb, an area of the brain critical to the sense of smell. His photo could
hang in any Washington, D.C., gallery, but it also educates about the complexity of
the brain.
James L. Griffith, MD, chair of the Department of Psychiatry and Behavioral
Sciences and Leon M. Yochelson Professor of Psychiatry and Behavioral Sciences,
was honored for his lifetime of work leveraging the power of religious belief in
psychiatric therapy, especially for those of us suffering profound traumas.
You also can read about virtual reality technology that allows our neurosurgeons
to map complex surgeries to remove tumors or treat blood vessel abnormalities
before they enter the operating room. Here again, the images demonstrate the
beauty and complexity that is the human brain.
Director of the George Washintgon University (GW) Institute for Neuroscience
Anthony-Samuel LaMantia, PhD, professor of pharmacology and physiology,
was honored recently in two ways. First, the sixth edition of LaMantia’s textbook,
Neuroscience, was published. The book has become the standard for the field and
is the source for budding neuroscientists to receive their education. Second, GW’s
School of Medicine and Health Sciences (SMHS) acknowledged his excellence by
naming him the Jeffrey Lieberman Professor of Neurosciences. Joining LaMantia
as an endowed professor is GW resident alumnus Brandon Kohrt, MD, PhD, RESD
’13, associate professor of psychiatry and behavioral sciences, who became the
Charles and Sonia Akman Professor in Global Psychiatry. Not only is an endowed
professorship a prestigious appointment at any academic institution, but it also
provides financial support of neuroscience research at GW and honors the donor
in perpetuity. Such endowments are the lifeblood of universities from the time they
were first established at Oxford University centuries ago.
Neurotransmitter further spans the breadth of the neurosciences with stem
cell treatments for multiple sclerosis and brain stem physiology that could lead
to potential therapies for sleep apnea. As you will appreciate, discoveries occur
through the collaboration of many scientists and physicians. This is the strength of
GW Hospital, GW Medical Faculty Associates, and SMHS.
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CONTEST HIGHLIGHTS THE ART
OF SCIENTIFIC RESEARCH AT SMHS
“[When choosing
a winner,] we didn’t
ask ‘Is this an
important scientific
advancement?’ or
‘Is this technique
important?’ We were
really just looking
at how attractive it
was. But beneath
these pretty images
are major advances
in our understanding
of biomedical
science and potential
medical advances.”
Alison Hall, PhD

THE BEAUTY OF SCIENCE
First-year MD student Aslam
Akhtar, PhD, is the inaugural
grand prize winner of the
George Washington University School of Medicine and
Health Sciences Art of Science
Contest. Akhtar’s image was
selected from the 12 images
submitted for consideration.

Looking at a winning submission for the first-ever
George Washington University (GW) School of
Medicine and Health Sciences (SMHS) Art of Science Contest, one might not know the bright purple and green colors represent olfactory bulb interneurons and astrocytes in the brain, but that’s the
beauty of art: there’s more to it than meets the eye.
The contest shows off the amazing research
medical students, graduate students, and postdoctoral fellows are conducting “through dynamic
and beautiful images,” said Alison Hall, PhD, associate dean for research workforce development and
professor of neurology at SMHS.
The four contest winners — chosen by a team of
SMHS deans, students, and staff — will have their images displayed in the SMHS Dean’s
Suite in Ross Hall.
Grand prize winner and first-year MD student Aslam Akhtar, PhD, said a push from
classmates and class discussions about the olfactory bulb neurons — the neurons responsible for our sense of smell — led him to enter his image in the contest.
“I hope when someone walks by they reflect more about the deeper meaning,”
Akhtar said, adding hopefully “it will create an appreciation for the complexity of the
brain and the lifelong impacts that diseases of the brain can have.”
The image, he added, arose from his neurodevelopmental research into how neurons in the brain develop from neural stem cells after birth. “There are only a few regions of the brain where neurons are generated after birth, the olfactory bulb being
one of these regions,” he said. “If we can better understand the characteristics of the
stem cells that generate these neurons, we can apply that knowledge toward replacing
or supporting cells lost in neurodegenerative diseases.”
This year, 12 images were submitted for consideration, and Hall said she hopes even
more images, reflecting even broader approaches to research, are submitted in the
years to come. The contest will be an annual event.
Winner Shabnum Patel, PhD, a post-doctoral fellow with the GW Cancer Center,
submitted an image showing her immunotherapy research. “For this image, we were
focused on making Mucor-specific T-cells to fight the fungal infection Mucormycosis,”
she said. “We thought [the contest] would be a nice way not only to display a beautiful
picture, but also to get people interested in the type of research that we do.”
Hall added that the beauty of the entries is what makes the contest so interesting.
“[When choosing a winner,] we didn’t ask ‘Is this an important scientific advancement?’ or ‘Is this technique important?’ We were really just looking at how attractive
it was,” Hall said. “But beneath these pretty images are major advances in our understanding of biomedical science and potential medical advances.”

“I hope when someone walks by they reflect more about the deeper meaning.
[Hopefully] it will create an appreciation for the complexity of the brain
and the lifelong impacts that diseases of the brain can have.”
Aslam Akhtar, PhD, first-year MD student
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SETTING THE STANDARD FOR NEUROSCIENCE,
RESEARCHERS RELEASE SIXTH EDITION OF ACCLAIMED TEXT
Academic publisher Sinauer Associates announced this fall the release of the sixth
edition of Neuroscience, co-authored and co-edited by Anthony-Samuel LaMantia,
PhD, director of the George Washington University (GW) Institute for Neuroscience
(GWIN), Jeffrey Lieberman Professor of Neurosciences, and professor of pharmacology
and physiology at GW’s School of Medicine and Health Sciences (SMHS). Since its initial
publication, the comprehensive text has grown to become a standard in the dynamic
field of neuroscience, spanning topics from cellular signaling to cognitive function.
The best-selling and most widely used text for medical and undergraduate neuroscience courses has been a combined effort over its many years, according to LaMantia, and features co-authors and editors from Duke Institute for Brain Sciences; Duke
University School of Medicine; Lee Kong Chian School of
Medicine, Nanyang Technological University, Singapore;
“It’s an interesting
the Max Planck Florida Institute for Neuroscience; and the
time for this
University of Pennsylvania.
This recent edition is also the first published since Sinauaspect of academic
er became a subsidiary of Oxford University Press. “That
means that the book … has a larger audience as part of the
science, education,
Oxford University Press orbit,” said LaMantia.
neurosciences,
“I think everyone is very enthusiastic,” he added. “It’s an
interesting time for this aspect of academic science, educaand academic
tion, neurosciences, and academic publishing.”
New to this edition is an expanded cognitive
publishing.”
neuroscience unit, with chapters on attention, decisionmaking, and evolution of cognitive functions; an updated
Anthony-Samuel
neural signaling unit; and new clinical applications boxes
LaMantia, PhD
and web essays.

A NEW RELEASE
The sixth edition of Neuroscience, co-authored and co-edited
by Anthony-Samuel LaMantia,
PhD, was released by Sinauer
Associates, a subsidiary of
Oxford University Press, in the
fall of 2017. Since its initial
publication, the textbook has
become the most widely used
text for medical and undergraduate neuroscience courses.
It is now a standard in the
dynamic field of neuroscience.

DRAWING STRENGTH FROM THE SPIRITUAL SIDE

WHERE RELIGION
MEETS PSYCHIATRY
James L. Griffith, MD, received
the American Psychiatric Association’s Oskar Pfister Award. The
award, which is named after a
Lutheran minister, is presented
to individuals who have made
outstanding contributions to the
understanding of the interplay
between religion and psychiatry.

James L. Griffith, MD, chair for the Department of Psychiatry and Behavioral Sciences
and Leon M. Yochelson Professor of Psychiatry and Behavioral Sciences at the George
Washington University School of Medicine and Health Sciences, received the Oskar
Pfister Award from the American Psychiatric Association during the association’s Institute on Psychiatric Services: The Mental Health Services Conference in New Orleans.
The award — named in honor of Oskar Pfister, a Lutheran minister who studied and
used psychoanalytic principles in his work — is presented annually to individuals who
have made outstanding contributions to the understanding of the interplay between
religion and psychiatry.
Over the course of his career, Griffith has focused on helping clinicians learn how
to draw from patients’ spiritual resources when helping them to cope and sustain resilience in the face of disease, disability, and suffering. He has become a global mental
health leader, providing psychiatric treatment for immigrants, refugees, and survivors
of political torture.
At the meeting, Griffith also delivered the Oskar Pfister Award Lecture, “Hope Modules: Brief Psychotherapeutic Interventions to Counter Despair from Chronic Adversities.” Griffith described his work developing brief interventions to help patients sustain
hope despite demoralizing life circumstances and methods for teaching trainees and
other clinicians.
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GW Expands Presence
at Neuroscience 2017

T

he George Washington
University (GW) had an
enhanced presence at
one of the largest neuroscience
conferences
in the world, The Society
for Neuroscience 2017
Annual Meeting, held at the Walter E.
Washington Convention Center in midNovember.
The meeting drew more than
30,000 scientists from throughout the
world to Washington, D.C., for a week
of presentations and intellectual exchanges about the brain, how it works,
how it develops, and the challenges of
solving brain diseases.
Anthony-Samuel LaMantia, PhD,
director of the GW Institute for Neuroscience, Jeffrey Lieberman Professor of Neurosciences, and professor
of pharmacology and physiology at
GW’s School of Medicine and Health
Sciences (SMHS), said the meeting
comes to Washington, D.C., every three
years, and this year GW’s presence was
expanded to include satellite sessions
held on the GW Foggy Bottom campus.
LaMantia added that both the
promise and challenge of having such
a prominent role at the meeting is to
continue to expand GW’s neuroscience community to be a part of all the
changes happening in the field. The
last several years have brought robust growth to neuroscience research
at GW, and there is a commitment to
continue to grow in this critical area of
biomedical research.
Throughout the meeting, GW neuroscientists from SMHS, the Columbian College of Arts and Sciences, and
the Milken Institute School of Public
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Neuroscience 2017 drew more than 30,000 scientists
from throughout the world to Washington, D.C.
Health at GW presented nearly 60 research posters.
SMHS faculty also spoke at the
event, including Robert H. Miller, PhD,
senior associate dean of research, Vivian Gill Distinguished Research Professor, and professor of anatomy and
regenerative biology; Vittorio Gallo,
PhD, associate dean for child health research and professor of pediatrics; and
Kevin Pelphrey, PhD, director of the
GW Autism and Neurodevelopmental
Disorders Institute and Carbonell Family Professor in Autism and Neurodevelopmental Disorders.
One of the main takeaways from
the event, LaMantia said, is the growth
in addressing translational issues of
neuroscience. “I think we want to develop more aspects of translational
research at GW, because that is something more and more being featured
in the field,” he said. Recent progress,
attendees reported, hold promise for
new approaches to disorders that previously were thought insoluble. These
include neurodegenerative disorders
like Alzheimer’s and neurodevelopmental disorders like autism spectrum
disorder.
“I think it will be interesting in 2020,
when Neuroscience returns to D.C., to
see [what direction research has taken
the profession],” LaMantia added. “The
field has grown, but it’s also changed. I
am hopeful that will continue, and that
we will even have a bigger presence in
2020.”

THE MEETING OF PEERS
The Society for Neuroscience 2017
Annual Meeting was held at the
Walter E. Washington Convention Center in mid-November.
The conference, one of the
largest neuroscience conferences in the world, will return
to Washington, D.C., in 2020.

Brandon Kohrt Installed as
Charles and Sonia Akman
Professor in Global Psychiatry

S
CHANGING THE
LIVES OF CHILDREN
Brandon Kohrt, MD, PhD,
RESD ’13, (right) was recently
installed as the Charles and Sonia Akman Professor in Global
Psychiatry. In his career, Kohrt
has worked to reduce stigma
among youth and adults affected by mental illness, political
violence, and physical illness
in countries such as Nepal,
Liberia, South Africa, Ethiopia,
Mongolia, Haiti, and India.

angeeta, Ramesh, Asha.
Those are names of children whose lives were
restored thanks to the
efforts of global mental
health expert Brandon
Kohrt, MD, PhD, RESD ’13, associate
professor of psychiatry and behavioral
sciences at the George Washington
University (GW) School of Medicine
and Health Sciences (SMHS). Kohrt
shared their stories at his installment
as the Charles and Sonia Akman Professor in Global Psychiatry.
“We are all part of the George
Washington University because of the
dedication to improving the quality of
the human experience and to reducing human suffering through research,
education, and service,” Kohrt said. “I
am deeply grateful … for the opportunity to pursue this mission to its fullest
extent.”
The endowed fund was made in
memory of the parents of Leonard
C. Akman, MD ’43, a pioneer in heart
transplantation and cardiac catheterization and cousin to Jeffrey S. Akman, MD ’81, RESD ’85, vice president
for health affairs, Walter A. Bloedorn

Professor of Administrative Medicine,
and dean of SMHS. When Leonard Akman passed away, he left SMHS a $3.2
million gift to support a variety of initiatives, the choosing of which he left to
his cousin.
Kohrt has worked on mental health
in Nepal since 1996 and as an adviser
to the Transcultural Psychosocial Organization in Nepal since 2006. He
also has collaborated with The Carter
Center Mental Health Program in Liberia since 2010, and he has investigated
the mental health consequences of
and designed interventions for child
soldiers and earthquake survivors in
Nepal.
In addition, Kohrt collaborated on
the development of a Nepali schoolbased youth suicide prevention program. And, in Liberia, Kohrt designed
programs to reduce stigma among
youth and adults affected by mental illness, political violence, and the Ebola
outbreak. “He has worked in South
Africa, Ethiopia, Mongolia, Haiti, and
India,” said Forrest Maltzman, provost
and executive vice president for academic affairs at GW. “He is changing
the world, and he is never sleeping.”

“We are all part of the George Washington University because of the
dedication to improving the quality of the human experience and to
reducing human suffering through research, education, and service.”
Brandon Kohrt, MD, PhD, RESD ’13
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Saving Sleep,
Counting Sheep
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GEORGE WASHINGTON MEDICAL FACULTY
ASSOCIATES CENTER FOR SLEEP DISORDERS
FOCUSES ON HELPING PATIENTS CATCH SOME Zs
BY KATHERINE DVORAK

W

e’ve all been there at some
point, tossing and turning
and counting down the
minutes before the alarm
goes off and the day begins. For more than a third
of the American population, however, sleep disorders such as insomnia,
sleep apnea, narcolepsy, and restless legs syndrome make those struggles a nightly occurrence,
often putting those precious seven to eight hours of
sleep out of reach.
Insufficient sleep is more than an inconvenience;
it can cause serious long-term cardiac and neurological problems, including increased risk of hypertension, stroke, and even cognitive impairment,

“More work is beginning to touch on the hypothesis
that sleep apnea might be involved in more longterm problems, such as Alzheimer’s disease.”

David Mendelowitz, PhD

according to David Mendelowitz, PhD, vice chair
and professor of pharmacology and physiology at
the George Washington University (GW) School of
Medicine and Health Sciences (SMHS).
Mendelowitz says there’s growing recognition
of the intersection between conditions such as obstructive sleep apnea and serious neurologic disorders. “More work is beginning to touch on the hypothesis that sleep apnea might be involved in more
long-term problems, such as Alzheimer’s disease,”
he says.
One of Mendelowitz’s efforts is finding novel
treatments for obstructive sleep apnea, a chronic
condition involving an intermittent blockage of the
upper airway during sleep, which is associated with
snoring, pauses in breathing, and excessive sleepiness. More than 18 million adults in the United States
suffer from the disorder, according to the National
Sleep Foundation.
“There are very significant cardiovascular consequences of sleep apnea. We’re interested in what
changes in the central nervous system, particularly
in the brain stem, occur during sleep apnea to initiate and/or sustain these cardiovascular diseases,”
Mendelowitz says. “At the same time, we want to
identify targets of opportunity for treating sleep apnea to reduce the dysfunction of the cardiovascular
system and reduce the risks of adverse cardiovascular events.”
However, sleep apnea is often underdiagnosed.
The closure of the airway, says Vivek Jain, MD, medical director of the GW Medical Faculty Associates’
(MFA) Center for Sleep Disorders and associate professor of medicine at SMHS, often goes unnoticed
during sleep. “Most patients won’t recognize they
have sleep apnea,” Jain says. “For every patient [with
sleep apnea] we see in the clinic, or in general in the
country, I think there are probably two out there who
haven’t been tested.”
Jain adds that the symptoms of sleep apnea —
fatigue, daytime sleepiness, or interrupted sleep
— usually are what drive patients to the Center for
Sleep Disorders.
Patients diagnosed with sleep apnea are often
prescribed a continuous positive airway pressure
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For more than a third of the American population,
sleep disorders such as insomnia, sleep apnea,
narcolepsy, and restless legs syndrome make
getting enough sleep a nightly struggle.
therapy (CPAP) device. The machine, which includes
a plastic mask that fits over a user’s nose and sometimes mouth, is worn during sleep and helps to increase air pressure so the airway doesn’t collapse
when a person inhales. CPAP machines are 100 percent effective when patients use them, notes Jain.
Unfortunately, he adds, they have low compliance.
“At least 50 percent of the patients who are prescribed CPAP machines discontinue their use or use
them for less than four hours a day,” Mendelowitz
says. “It’s extremely uncomfortable, awkward, and
it’s not the sexiest thing in the world to be sleeping
with a mask on your face.”
Currently there are no pharmacological treatments for the disorder, he notes. But, Jain and Mendelowitz are collaborating on translational research
in the hope of discovering such an option.
“Two graduate students in my lab … were looking at a pathway from the hypothalamus to neurons

SIGNS OF SLEEP APNEA
>> Snoring that’s interrupted with periods of quiet
>> Snoring that resumes with a loud sound as
breathing restarts
>> Morning headaches
>> Frequently falling asleep during the day
>> Being easily irritated
>> Depression
>> Difficulty remembering things
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that are important in autonomic control. They found
that there’s a specific population of neurons in the
paraventricular nucleus of the hypothalamus that
releases oxytocin, which in turn excites autonomic
parasympathetic neurons to the heart and restores
autonomic balance,” Mendelowitz explains. “We
found in our work that activation of these oxytocin
neurons prevented the hypertension that occurs in
an animal model with sleep apnea.”
After the discovery, Mendelowitz approached
Jain about conducting a pilot project to test if oxytocin would be beneficial in patients with sleep apnea.
Eight patients diagnosed with sleep apnea presented for a sleep study and received a dose of oxytocin
via a nasal spray before bed.
Their initial findings were positive, Jain and Mendelowitz say, showing that oxytocin may play a role
in shortening apnea duration and lessening nighttime arousals. “These patients did subjectively feel
better. [It’s an] uncontrolled, non-blinded, non-randomized placebo control study, but it’s a good beginning,” Jain says.
While sleep apnea is one of the main disorders
for which patients seek out the sleep center, it’s not
the most common, Jain says. Although people may
not see it as a disorder, sleep deprivation is one of
the most prevalent sleep conditions, he notes, and
insomnia, the inability to fall asleep or return to
sleep in the night, comes in second.
In addition, says Mendelowitz, a lot of these conditions can be overlapping; someone can have both
sleep deprivation and sleep apnea.
Another sleep disorder, which affects 10 percent
of U.S. adults, is restless legs syndrome. Elias Karroum, MD, PhD, assistant professor of neurology at
SMHS and a neurologist at the MFA, whose research
focuses on the condition, notes that restless legs
syndrome differs from other sleep disorders be-

“People talk about impairment of alcohol,
but we should also open the conversation
on impairment due to sleep problems.”
Vivek Jain, MD

cause it happens while a person is awake.
Also known as Willis-Ekbom Disease, the disorder causes uncomfortable sensations in the legs
and an irresistible urge to move them. It happens to
people in the evening or at night while they are still
awake and can prevent people from falling asleep,
which can lead to insomnia, says Karroum.
“I like to think of it as a resting wakefulness disorder
with a core sensory component of feeling the need to
move the limbs,” he explains. In addition, in up to half
of the patients, the abnormal sensations are not only
unpleasant, but also quite painful. Karroum says one
reason he is studying this disorder is because there is
still a lot to learn about it, including what causes the
sensations and pain in these patients.
Two to 3 percent of U.S. adults experience moderate to severe cases of restless legs syndrome,
in which the sensation occurs two to three times a
week and negatively affects a patient’s daily life,
Karroum says. For those patients, he’ll recommend
a small dose of dopamine agonists, which mimic the
neurotransmitter dopamine in the brain.
Jain says while research on sleep has picked up
in the last 20 years, “there’s still more to be done.”
“People may blow a lack of sleep off, saying ‘oh, I
get six hours of sleep at night,’ and they don’t even
bat an eye. But six hours of sleep is not right. It really
has its own independent negative effects on health,
including many cardiovascular diseases, obesity,
and diminished cognitive awareness,” he says. “People talk about impairment of alcohol, but we should
also open the conversation on impairment due to
sleep problems.”

WHAT TO EXPECT AT THE SLEEP CLINIC
When arriving at the MFA Center for Sleep Disorders,
patients give detailed histories of their sleep patterns.
Some of the questions asked include: What time do you
go to bed? How many minutes does it take you to fall
asleep? Do you fall asleep at inappropriate times? Do
you snore?
If overnight monitoring is deemed necessary to diagnose the right sleep disorder, a patient will either be
brought to the lab — located at 2021 K St., NW — for a
sleep study, or given monitors to take home.
At home: Home monitors are not as extensive as
those used in clinic-based sleep studies. These devices
simply record breathing and oxygenation. If the home
monitor shows a mild case of a disorder such as sleep
apnea, then an in-lab study may be requested to confirm the findings.
In the lab: Patients spend the night in a hotel-like
setting to have their sleep monitored. Study arrival time
is 8:30 p.m., at which point a patient is prepped for a
polysomnography test, which takes about 45 minutes.
The test looks at brain-wave patterns and physiologic
function during sleep. Sensors are placed on the face
and scalp to measure electrical activity in the brain, a
sensor by the nose records respiration rates, and oxygenation is measured using a finger probe, and belts
on the chest and abdomen measure breathing effort.
While it’s expected that patients won’t have a perfect night’s sleep in the lab — people rarely do when not
in the comfort of their own beds — disorders like sleep
apnea will surface even if subjects only get a few hours
of shut eye.
“Even if you sleep on the Metro, or fall asleep at
home on the couch, you will have sleep apnea,” says
Jain. “It’s a sleep phenomenon; it’s not a stress-related
phenomenon or environment-related phenomenon.”

Insufficient sleep can cause serious long-term cardiac
and neurological problems, including increased risk of
hypertension, stroke, and even cognitive impairment.
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Of Mice and MSCs
MESENCHYMAL STEM CELL RESEARCH OFFERS PROMISE AND PUZZLES

C
Robert H. Miller, PhD, senior associate dean
for research, Vivian Gill Distinguished
Research Professor, and professor of
anatomy and regenerative biology
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BY STEVE GOLDSTEIN

ell therapy is number one on the research rock charts. The practice of
transferring intact, live cells into a patient to help lessen or cure a disease is rapidly expanding, and in the United States alone, there currently are more than 15,000 active clinical trials in the field.
One of the most promising therapies is the transplantation of mesenchymal stem cells (MSCs), which are multipotent cells present in multiple tissues including umbilical cord, bone marrow, and fat. MSCs give
rise to bone, cartilage, muscle, and adipocytes (fat cells), which promote marrow adipose tissue. These versatile cells are particularly suited as a cellular therapy for autoimmune diseases, including multiple sclerosis (MS), and they have immunosuppressive
and tissue repair properties that lend themselves to therapy for inflammatory diseases.
Based on their success in treating animal models of MS-like experimental autoimmune
encephalomyelitis (EAE) — a brain-inflammatory disease of the central nervous system
that erodes the myelin sheath protecting nerves — MSCs have moved rapidly into clinical trials for MS.
Such a trial is described in a research paper co-authored by Robert H. Miller, PhD,
senior associate dean for research, Vivian Gill Distinguished Research Professor, and
professor of anatomy and regenerative biology at the George Washington University
School of Medicine and Health Sciences. Despite the hope and promise resting on
MSCs, the clinical trial failed to show significant improvement, resulting in the conclusion that central nervous system damage diminishes the therapeutic function of bone
marrow MSCs.

LOOKING FOR A TREATMENT
FOR MULTIPLE SCLEROSIS
Robert H. Miller, PhD, led
a clinical trial to transplant
mesenchymal stem cells (right).
These versatile cells are particularly suited as a cellular therapy
for autoimmune diseases,
including multiple sclerosis.

“This is a pretty interesting cell therapy — it’s one of the
most interesting of the therapies around,” Miller says. “There
are something like 27 MSC clinical trials going on now.”
In the paper, Miller reports that bone marrow MSCs derived from mice with encephalomyelitis weren’t as effective at treating the disease as those from uninfected mice.
Similarly, the cells derived from MS patients showed less
therapeutic efficacy in treating EAE, and researchers also
observed the secretion of higher levels of some pro-inflammatory proteins. The results, showing diseases such
as EAE and MS reduce the therapeutic effectiveness of bone marrow MSCs, are leading
researchers to rethink the use of a patient’s own MSCs as a potential MS treatment.
Despite the outcome, Miller is upbeat about the therapeutic value of MSCs, recalling
how, before this study, they found human mesenchymal stem cells were very effective
in reducing the disease burden in animals. “When we got that data, I went to see Jeff
Cohen at the Cleveland Clinic … and he put the clinical trial together with 12 patients —
all of whom had MS,” says Miller.
As Miller explains in the paper, MSCs are defined experimentally as a population
of cells that “stick to things” and can generate the major connective tissue derivatives,
such as fat and mesenchymal tissues. They also are self-renewing, so they can divide.
“We know they live in bone marrow, and we know they live in fat and adipose tissues,
and some people think they are parasites that live around vasculature in many organs,”
Miller explains. “They are relatively hard to isolate.”
Putting human MSCs into mice, according to Miller, was effective at reducing disease, and putting mouse cells into mice is also effective at reducing disease. In human
trials, however, the treatment has not proven to be as effective in reducing disease.
“What this paper argues is that it’s not necessarily true that the human MSCs are bad
or that the human disease is different — although we don’t know that,” Miller says. The
outcome was determined by what happened to the bone marrow before cells were
isolated. In the trial, patients came in, had bone marrow taken from their hips, the MSCs
were isolated, and they were expanded in a dish and then reinfused into the vasculature. “All the clinical trials had used that paradigm because the FDA feels quite strongly
about the possibility of rejection,” says Miller. “The studies in mice were done using
normal human-derived cells — not MS-derived cells.”
Thus, according to Miller, the reason the clinical trials didn’t work can be traced to
the source of the cells. “We were starting off with defective cells, in effect, and the
clinical trial was proof of that hypothesis,” says Miller. When diseased mice were infused
with normal cells and cells derived from MS patients, the MS-derived cells “didn’t work
nearly as well.” An experiment to test the influence of genetics also proved negative.
Again, the effect of diseased and normal MSCs in genetically identical mice was compared. It clearly isn’t genetics, asserts Miller, “so it says something about the disease has
compromised the capability of those cells, and that’s why I think the clinical trials failed.”
Miller is sanguine about the trials. “This is the way translational science works. You
make an observation in the laboratory. You put it into a clinical trial. The clinical trial tells
you something. You go back to the laboratory based on that knowledge, and then you
redesign the clinical trial based on that new information.” He concedes, however, that
he was “really disappointed when the trials didn’t work because we felt sure it was going
to work — based on the animal data.”
Still, next steps are planned based on the outcome of the failed trials. Miller suggests that
“if Jeff Cohen had taken my cells and put them in an MS patient, I hypothesize they would
have worked.” But allergenic transplants are frowned upon by the FDA because they carry a
higher rate of rejection, and thus more risk for people in trials.
“Will this ever be the best way to treat MS? I don’t know,” says Miller. “But I’d rather
have an MSC transplant, even an allergenic MSC transplant, than a whole bone marrow
transplant, which is what some people are doing now for some MS patients.”

There are currently more than
15,000 active cell therapy clinical
trials in the United States.
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A Virtual Reality Check
USING TECHNOLOGY FOR EDUCATION AND PREOPERATIVE PLANNING
BY CAROLINE TRENT-GURBUZ
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he black and bulky headset fits snugly, though Aalap Herur-Raman, senior
virtual reality program lead from Surgical Theater, can adjust the straps
as needed. When he taps on the keyboard in front of a pair of computer
screens, it’s impossible not to peer
through the binocular-like eyepiece as the image — upside down, per the surgical point of
view — zooms into a skull, revealing a maze of
colorful vasculature and brain matter.
“There are the blood vessels,” points out
Anthony Caputy, MD, chair of the Department of Neurological Surgery and Hugo V. Rizzoli Professor of Neurological Surgery at the
George Washington University (GW) School
of Medicine and Health Sciences (SMHS), on
the corresponding computer screens. HerurRaman adjusts the opacity of the brain matter
— thick and gray — until it fades away. “You can
always add some of
VIRTUAL REALITY the brain matter back
Through Precision Virtual in,” Caputy continReality, a product based on ues, “so you can see
an F-16 flight simulation
where the brain is in
program, medical professionals can see abnormali- relation to the blood
ties in the brain, such as vessels. You can even
the tumor appearing see where the tumor
behind the left eye socket is in relation to the
in the patient scan above. blood vessels.”

The tumor, a bright green mass appearing
behind the left eye socket, is the target of the
unique device, which provides medical professionals and patients a 3-D glimpse of a specific condition.
Precision Virtual Reality (VR), a product
of Ohio-based company Surgical Theater, is
based on an F-16 flight simulation program. A
chance meeting at a coffee shop with a neurosurgeon led the company’s founders — both
Israeli Air Force officers — to tweak their simulator program for neurological surgery.
“[It’s] actually not terribly complex,” explains Todd Goldberg, vice president of sales
at Surgical Theater. “We are essentially a VR
studio; instead of making music or movies, like
you think of studios in entertainment, we make
personalized medical content that’s useful for
patients and surgeons. The components consist of a very high-powered computer, with the
latest, greatest, and most advanced graphics
processing unit, or GPU, and the latest and
greatest Intel chip. But the real brain of the
system is the software itself.”
That software, which identifies potential
surgical paths for brain and spinal conditions,
is key for the SMHS Department of Neurological Surgery’s approach to patient outcomes.
“It’s a huge part of this three-pronged process:
education, patient engagement, and surgical
planning,” says Jonathan Sherman, MD, associate professor of neurological surgery at SMHS,
who, as a longtime proponent of the tool, led
the campaign to bring it to GW Hospital.
Right now, budding neurological surgeons
have access to the Ammerman Lab, a microsurgical lab in SMHS’ Ross Hall that focuses on
skull base, minimally invasive, microvascular,
and spine surgeries, as well as basic science
research. There, residents can literally get a
“feel” for surgery — the texture of tissues, vibrations, additional movements — but with
Precision VR, they get a more in-depth understanding of the structural aspects of the brain
and spine.

GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES

13

From a patient perspective, Precision Virtual Reality
is a powerful tool for edification and engagement.
GW Hospital patient Roodelyne Jean-Baptiste, for example, previously had two surgeries to treat brain tumors, which were “brutal,”
she says. Last winter, she was told she needed
a third surgery, but she balked, thinking her
tumor was relatively small. Her physician (Sherman) insisted, however: “He said, ‘No, we can’t
hold off because of the size.’ We had to move
so fast because it was already affecting me. The
tumor was making me unable to eat and dizzy.”
After her surgery, Sherman used JeanBaptiste’s MRIs and Precision VR to explain
the complexity of her tumor. “He actually
showed me exactly what he was talking about
when he had to avoid a cut and what he had to
stay away from when he went into the brain,”

AT A GLANCE
Anthony Caputy, MD,
discusses the results
of the Precision
Virtual Reality with
patient Danielle
Collins. At the age
of 27, Collins was
diagnosed with a
ruptured arteriovenous malformation,
an abnormal connection between the
arteries and veins.
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“[When it comes to] the education of residents and students, even professionals, Precision VR will help them better understand what
we’ll encounter in surgery and the risks of the
surgery,” Caputy says. “You can show [them],
here’s the anatomy, here’s the motor pathways,
here’s the sensory pathways, here’s the optic
pathways. You can cut everything out around
the pathway you want to show, whereas before, you would show it with brain slices. Their
mind would have to put the 3-D together.”
Those complementary aspects, he adds,
are critical to education. “We need both of
those labs to train people.”
From a patient perspective, the tool is equally powerful for edification and engagement.
“Looking at an MRI or a CAT scan, patients
almost tune you out because they don’t quite
understand everything that’s going on, and
they think they have to be a physician or health
care professional to interpret a CAT scan or
MRI,” says Michael Rosner, MD, vice chair of the
Department of Neurosurgery and professor of
neurological surgery at SMHS. “To be able to
take all that data and just put it in the threedimensional model is … very, very helpful.”
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she recalls. “If I had
IN THEATER
had [the 3-D image]
Michael Rosner, MD,
from the first time
addresses an audience at
I encountered the the George Washington University School of Medicine
procedure, I would
and Health Sciences on the
have never hesitated
topic of Surgical Theater.
to do it. You can actually see what the
doctor is saying instead of agreeing with them
just to agree with them.”

While Jean-Baptiste was able to get a better handle on her specific tumor, Sherman
and his fellow neurological surgeons gained
insight into what surgical strategies worked
best. With a tumor, for example, Precision VR
includes arrows for possible surgical entries,
and surgeons get a clear view of what obstacles they may need to navigate around to ensure a successful procedure.
“Now, we can plan out ahead of time and really see the anatomy,” Sherman says. “It helps
us get a better perspective on what we’re going to do surgically. We can use this technology to plan surgical [techniques], and then in
the OR, we can actually use it to navigate to
what we’re doing.”
Caputy agrees, adding that by visualizing
the environment, surgical teams can identify
areas of concern ahead of time. “Surgeons
can devise a strategy that best allows them
to achieve their goal: tumor removal and the
preservation of functions,” he says. “You want
the most effective approach, and Precision VR
can help you plan for that.”
GW Hospital was the first hospital in the
mid-Atlantic region to offer the tool, a boon
for local patients and surgeons. “This is yet
another way that we are moving the care standard higher at GW Hospital,” says Kimberly
Russo, MBA, MS, CEO and managing director
of GW Hospital.
Although the tool is primarily geared toward neurology-related conditions and procedures at GW Hospital, its potential extends far
beyond its technological appeal. As Goldberg
explains, health care has a tendency to create
silos; Precision VR, however, promises to break
down those divisions and allow for better collaboration.
“This is one of those rare technologies
that has come along that builds bridges
among different members of the health
care team, among different departments of
the hospital, and certainly among patients

and their families,”
A PEEK INTO THE BRAIN
Patient Danielle Collins
Goldberg says.
Sherman likewise peeks into her brain through
the Precision Virtual Reality
believes that the
headset.
Collins said the detool’s value isn’t limvice
provided
a tangible way
ited to neurological
to understand the surgical
surgery. “Ultimately,
plan, and made her feel like
we’re [trying] to get she was a part of the process.
this across disciShe said being able to see
plines,” he explains.
something that is undetect“My goal is that this
able by sight took away part
isn’t just a neurosurof the fear of the unknown.
gical tool; this is …
something we can
use for all areas of subspecialty in surgery.
We’re just touching the tip of the iceberg of
what our potential is with this technology.”
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Taking Away the
Fear of the Unknown
VIRTUAL REALITY GIVES PATIENTS THE INFORMATION TO ACT

A MIGRAINE TURNS OUT
TO BE LIFE-THREATENING
A sharp pain in her head
forced Danielle Collins
to leave a Pilates class
early. After two days of pain,
Collins decided to seek
medical help. The pain she
was feeling stemmed from
life-threatening bleeding in
her brain due to a ruptured
arteriovenous malformation,
an abnormal connection between the arteries and veins.
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BY KATHERINE DVORAK

n a Monday in early
June 2017, Danielle
Collins went to Pilates like any other
day. But during the
class, she felt a sharp
pain in her head, forcing her to leave
early. She chalked it up to a bad migraine, but after two days of suffering
through the pain, Collins decided to
see a doctor, only to discover she was
experiencing life-threatening bleeding
in her brain.
Collins, who works as a realtor at
Chevy Chase, Maryland-based Wydler
Brothers Real Estate, found out at 27
years old that her brain was bleeding
due to a ruptured arteriovenous malformation (AVM), an abnormal connection between the arteries and veins.
“I was running 8 miles five times a
week before this happened,” Collins

says, adding that she has always been
health conscious. “I hadn’t taken Advil,
hadn’t had a drink of alcohol, hadn’t
had anything in almost seven years. So
I didn’t take Aleve or Excedrin … which
would have thinned my blood and
probably killed me.”
Collins soon found herself at the
George Washington University (GW)
Hospital looking at images of the inside
of her brain. The device used, Precision
Virtual Reality (VR), offers 3-D views of
medical conditions and helps identify
possible surgical paths.
“It provided a tangible way to understand the surgical plan, and made me
feel like I was truly a part of the process,”
she says. “When you have an injury on
your body, like a gash on your arm, you
can see that. But when something is undetectable by sight, to provide sight to
the areas that would be blind to you is
incredible. It took away part of the fear
of the unknown.”
Over the next 10 days at GW Hospital, Collins received two angiograms, an
MRI, CAT scans, and a craniotomy. She
expressed sincere thanks for everyone
who helped her during her time at GW,
including Anthony Caputy, MD, chair
of the Department of Neurological
Surgery, and Wayne Olan, MD, director of interventional and endovascular
neurosurgery at GW’s Comprehensive
Stroke Center.“This was the best thing
that ever happened to me,” she says.
“No day is a bad day to me anymore; I
woke up this morning.”
Only months removed from her surgery, Collins was back at work and back
to her morning runs. “Running is time to
clear my head,” she says. “I run because
I want to live a long life, I want to have a
healthy body.”
Collins adds that she found peace in
a Bible passage from 2 Timothy 1:7 that
says: “For God has not given us a spirit
of fear, but peace (love), power, and a
sound mind.”
“On June 12, 2017, God, with the
team of surgeons and everyone at
GW, gave me a sound mind, and it was
something I never even knew I needed
because I had no prior knowledge of
the AVM,” she says. “It’s amazing what
minds collectively put together were
able to do to save my mind.”

ANTHONY-SAMUEL LAMANTIA,
director of the George Washington University (GW) Institute for
Neuroscience and professor of
pharmacology and physiology at
the GW School of Medicine and
Health Sciences, has become
the inaugural Jeffrey Lieberman
Professor of Neurosciences.

A Measure of Success
ANTHONY-SAMUEL LAMANTIA HONORED FOR WORK DEFINING
THE ORIGINS OF A DEVASTATING NEURODEVELOPMENTAL DISORDER

I
“If one is to achieve any
measure of success in
his or her professional
and personal journey,
that success is built
upon the love, support,
and guidance of
family, friends, and
colleagues. They make
the journey possible.”
Anthony-Samuel LaMantia, PhD

n what he called a “milestone in
an odyssey from the Midwest
to the mid-Atlantic,” AnthonySamuel LaMantia, director of the
George Washington University
(GW) Institute for Neuroscience
and professor of pharmacology and
physiology at the GW School of Medicine and Health Sciences (SMHS), became the inaugural Jeffrey Lieberman
Professor of Neurosciences during an
installation ceremony. Surrounded by
colleagues, family, and friends, LaMantia beamed as he thanked them for the
moment.
“If one is to achieve any measure of
success in his or her professional and
personal journey, that success is built
upon the love, support, and guidance
of family, friends, and colleagues. They
make the journey possible,” he said.
LaMantia has played a pivotal role
in expanding the GW neurosciences
faculty and has been a catalyst for
partnerships and collaborations across
the school, the university, and with

Children’s National Health System, said
Jeffrey S. Akman, MD ’81, RESD ’85, vice
president for health affairs, Walter A.
Bloedorn Professor of Administrative
Medicine, and dean of SMHS.
At the outset of LaMantia’s distinguished career, he explored the organization and development of axon
pathways that connect the two hemispheres of the cerebral cortex and
helped develop new methods for observing neural circuits in living animals
over time. While an assistant professor
of neurobiology at Duke University, he
demonstrated that the forebrain, which
mediates learning, memory, and cognition, is built with the same molecular
tools that build limbs, hearts, and facial
bones. He used this work as a foundation for studying the pathogenesis
of DiGeorge, or 22q11 Deletion Syndrome, a genetic disorder that comes
with the highest known genetic risk for
autism and schizophrenia, as well as
heart, face, and limb malformations.
LaMantia
worked
with
the
professorship’s namesake, Jeffrey A.
Lieberman, MD ’75, now the Lawrence
C. Kolb Professor of Psychiatry and
chair of the Department of Psychiatry
at the Columbia University College
of Physicians and Surgeons, while the
two were at the University of North
Carolina (UNC) at Chapel Hill.
“I think it represents the tying together of so many threads in my life,”
Lieberman said, reflecting on the coincidence of LaMantia being picked as
the first recipient of the professorship.
It was “unbeknownst to Jeff [Akman]
when he orchestrated this,” he added,
but “Anthony was at Duke when I was at
UNC, and I actually played a big role in
recruiting him to UNC.”
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